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We tested the feasibility and toxicity of high activities Rhenium-186 hydroxyethylidene diphosphonate, with peripheral blood
stem cell rescue in patients with progressive hormone refractory prostate cancer metastatic to bone. Twenty-ﬁve patients
received between 2500 and 5000 MBq of Rhenium-186 hydroxyethylidene diphosphonate followed 14 days later by the
return of peripheral blood peripheral blood stem cells. Activity limiting toxicity was deﬁned as grade III haematological toxicity,
lasting at least 7 days, or grade IV haematological toxicity of any duration or any serious unexpected toxicity. Activity limiting
toxicity occurred in two of six who received activities of 5000 MBq and maximum tolerated activity was deﬁned at this activity
level. Prostate speciﬁc antigen reductions of 50% or more lasting at least 4 weeks were seen in ﬁve of the 25 patients (20%)
all of whom received more than 3500 MBq of Rhenium-186 hydroxyethylidene diphosphonate. The actuarial survival at 1 year
is 54%. Administered activities of 5000 MBq of Rhenium-186 hydroxyethylidene diphosphonate are feasible using autologous
peripheral blood peripheral blood stem cell rescue in patients with progressive hormone refractory prostate cancer metastatic
to bone. The main toxicity is thrombocytopaenia, which is short lasting. A statistically signiﬁcant activity/prostate speciﬁc
antigen response was seen. We have now commenced a Phase II trial to further evaluate response rates.
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Prostate cancer is becoming the most common cause of cancer
death in males. Of patients who die from the condition, between
80 and 100% have bone metastases. Bone metastases frequently
result in pain, pathological fracture, deformity and neurological
deﬁcit and have enormous social and economic implications. Most
patients with bone metastases will initially respond to primary
androgen deprivation therapy but the duration of this response is
variable with a median of 18 months. Once this strategy has failed,
second line treatments including corticosteroids, anti-androgens,
diethylstilbesterol and cytotoxic chemotherapy including estramus-
tine have only had limited success in preventing disease
progression with short-lasting subjective responses in approxi-
mately 30% of cases (Dearnaley, 1994; Tannock et al, 1996;
Pisters, 1999). The average survival in patients with hormone
refractory prostate cancer metastatic to bone is in the order of 8
months (Fossa et al, 1992; Kelly et al, 1993; Sridhara et al, 1995;
Small and Vogelzang, 1997). Radionuclides including strontium-
89, rhenium-186 and samarium-153 have been used in the pallia-
tion of bone metastases in prostate cancer (Lewington et al,
1991; Porter et al, 1993; Quilty et al, 1994; Kolesnikov-Gauthier
et al, 2000). Pain response occurs in about 70% of cases. A correla-
tion between injected activity and rates of pain control in prostate
cancer bone metastases have been demonstrated in radionuclide
therapy with Strontium-89 (Mertens et al, 1993).
Rhenium is a group VII metal with a similar labelling chemistry
to Technetium. The radionuclide Rhenium-186 (Re-186) is
produced by irradiation of enriched Rhenium-185 and decays with
the emission of a b particle (Emax 1.07 Mev) and a low abundance
(9%) g ray (137 Kev). Rhenium-186 combined with the bispho-
sphonate hydroxyethylidene diphosphonate (HEDP) was ﬁrst
suggested as a therapy for prostate cancer bone metastases in the
late 1970’s (Mathieu et al, 1979; Deutsch et al, 1986). Since then
several investigators have used Re-186 HEDP for the palliation of
bone pain in this group of patients with response rates ranging
from 30 to 80% with mean duration of response of 7 weeks
(Maxon et al, 1990, 1991). The activity limiting toxicity has been
shown to be thrombocytopaenia with leucopaenia playing a minor
role (de Klerk et al, 1994a). We postulated that by increasing the
administered activity of the radionuclide we can maximise the
palliative beneﬁt by delivering ablative doses of ionising radiation
to each metastasis. Re-186 HEDP was chosen for a number of
reasons. Firstly, it emits b rays, which deliver the therapeutic radia-
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of radionuclide distribution. In order to prevent major bone
marrow toxicity especially unrecovered thrombocytopaenia, autolo-
gous peripheral blood peripheral blood stem cell rescue (PBSCR)
was used in all patients. This technique has been used to protect
the bone marrow from the effects of high dose chemotherapy for
many years (Mangan, 1995). With a biological half-life of 49–
69 h (de Klerk et al, 1992) and a physical half-life of 87 h, the
effective half-life of Rhenium-186 is approximately 31–38 h. This
would lead to 51% activity present in the bone marrow by 9–
11 days post therapy and permit peripheral blood stem cell re-14
days after the treatment and before the expected platelet nadir
between day 21 and day 28.
A starting activity of 2500 MBq of Re-186 was chosen for the
study on the basis of previous work de Klerk et al (1994b) and
McCready et al (1999) which suggested a maximum tolerated activ-
ity of between 2500 and 2900 MBq for patients with prostate
cancer metastatic to bone without peripheral blood stem cell
support. In our own study (McCready et al, 1999) two patients
treated at activities of 2500 MBq experienced Grade III thrombocy-
topenia lasting 9 and 11 days.
MATERIALS AND METHODS
Eligibility
Eligible patients (Table 1) had progressive hormone refractory
prostate cancer metastatic to bone, after at least 6 months ﬁrst
line hormone therapy using androgen suppression. Progressive
disease was deﬁned as rising serum Prostate Speciﬁc Antigen
(PSA) on at least two consecutive readings despite ﬁrst line andro-
gen blockade, or worsening bone metastases on bone scan, or
increasing metastatic bone pain. All men gave written informed
consent to take part in the trial which had been approved by
the Royal Marsden NHS Trust and Institute of Cancer Research
ethics committee.
Investigation
The full evaluation of patients included full blood count, serum
biochemistry including liver function tests, alkaline phosphatase,
lactate dehydrogenase, and PSA, isotope (
99mTc ) bone scans, chest
radiograph, CT scan of chest, abdomen and pelvis, ultrasound of
kidneys, and bone marrow trephine and aspirate. Quality of Life
was assessed using the European Organisation for Research and
Treatment of Cancer (EORTC) core Quality of Life Questionnaire
version 1 (EORTC/QLQ-C30) (Aaronson et al, 1993). This was
administered before treatment and subsequently at weekly intervals.
Isotope (
99mTc ) bone scans were assessed prior to treatment
and graded from 1–4 according to severity using the method
described by Soloway et al (1988). Forty-four per cent (11 out of
25) had a score of 3, 36% (nine out of 25) a score of two and
20% (ﬁve out of 25) a score of one.
Treatment
Peripheral blood stem cell harvesting was performed at least 2
weeks before radionuclide therapy. Patients received 10 mgk g
71
of Granulocyte-Colony Stimulating Factor (Filgrastim) for 4 conse-
cutive days and underwent peripheral blood peripheral blood stem
cell collection on the fourth and ﬁfth days. We aimed to harvest
1610
6 CD34 positive peripheral blood stem cells and 2610
8
mononuclear cells per kg of body weight. These were then frozen
and retained for use post treatment.
On the day of radionuclide treatment, patients were admitted to
a radiation isolation room where intra-venous access was estab-
lished. A urinary catheter was inserted to minimise contact
between radioactive urine and the bladder during the ﬁrst 24 h.
Following instructions to the patient in relevant radioprotection
issues the Rhenium-186 HEDP was injected intravenously through
the side port of fast running saline infusion. The volume of
injected Re-186 HEDP averaged 5 ml. On the day of treatment,
Re-186 whole body planar scans were acquired. Full blood counts
were measured daily during the admission. In all patients radiation
levels decayed to acceptable radioprotection levels by day 4 at
which point the patient was discharged. Fourteen days post radio-
nuclide treatment, patients were admitted to a day ward for re-
infusion of their peripheral blood stem cells. A graphic illustration
of the treatment schema is shown in Figure 1.
Follow up and assessment
All patients entered on the study continued their current hormone
ablation therapy. Patients were then seen on a weekly basis to
monitor their haematological proﬁle, renal function and Quality
of Life until the platelet count had recovered which was usually
4 weeks. If grade III haematological toxicity was identiﬁed, daily
counts were taken until recovery to grade II toxicity or better.
Follow-up was then carried out at monthly intervals. A repeat bone
scan was performed at 6 weeks post treatment and then on a 3
monthly basis. During the work-up and follow up periods the
patients also received best supportive care including external beam
radiotherapy and analgesia as required for pain.
Deﬁnition of toxicity
The National Cancer Institute Common toxicity criteria (CTC)
version 2 (Trotti et al, 2000) was used to deﬁne haematological
toxicity grades. The activity administered to a patient is a measured
known quantity, however the absorbed radiation dose to any point
depends on the distribution, elimination and decay of the radio-
nuclide. Activity limiting toxicity (ALT) was deﬁned as grade III
or worse platelet toxicity (10 to 550610
9 l
71) or grade III or
worse leucopaenia (1.0 to 52.0610
9 l
71) of more than 7 days









Table 1 Patient entry criteria
1 Histologically conﬁrmed prostatic carcinoma
2 Two or more bone metastases, conﬁrmed by radiological osteoblastic lesions
or scintigraphic imaging
3 Rising PSA on at least two occasions or progressive disease despite ﬁrst line
androgen blockade of at least 6 months duration
4 Aged over 18 years
5 No malignancy other than prostate cancer in the past 5 yeasrs (excluding
basal cell carcinoma of the skin)
6 No non-skeletal prostate metastases (as determined by CT thorax, abdomen,
and pelvis)
7 No cardiovascular contra-indications to peripheral blood stem cell return.
(Initially an upper age limit of 70 years was set which was subsequently
changed with ethics committee approval)
8 EDTA clearance 480 ml per minute
9 Haemoglobin above 10 g dl
71
10 White cell count above 4610
9 l
71
11 Platelet count above 100610
9 l
71
12 No previously administered Strontium-89 chloride or any other radionuclide
(e.g.
186Re-HEDP,
153Sm-EDTMP) for the treatment of bony metastases
13 No commencement of new hormone therapy or withdrawal of anti-androgens
within 4 weeks
14 No cytotoxic chemotherapy or bisphosphonates within the previous 3 months
15 No unmanageable urinary incontinence. No clinically signiﬁcant complication of
bony metastases from prostate cancer, which might interfere with the assess-
ment of bone pain, e.g. spinal cord compression and/or pathological fracture
16 WHO performance status 0 or 1
17 Willing and able to comply with the protocol (including Follow-Up, Quality of
Life Questionnaire and Diary of Medication and adverse effects)
18 Written informed consent form
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level. If no ALT was observed, the next three patients were treated
at the next activity level. If one patient had an ALT, the group was
expanded to six patients. Maximum tolerated activity was deﬁned
if two or more patients out of six reached ALT.
Statistics
Actuarial survival was calculated using the method of Kaplan and
Meier (1958). Correlation between toxicity and activity, perfor-
mance status, bone scan score, pre-treatment PSA and alkaline
phosphatase levels was tested using non-parametric tests (Spear-
man correlation and Mann–Whitney U-tests). The PSA




Twenty-ﬁve patients were treated with radionuclide therapy. One
patient unfortunately developed spinal cord compression after
consenting to treatment, but never received Re-186 and is therefore
not included in the data analysis. All but one patient had rising
PSA levels. This patient had increasing bone pain, worsening bone
scan and rising alkaline phosphatase. His serum PSA measured
0.1 ng ml
71.
The median time from diagnosis of bone metastases to receipt of
Rhenium-186 HEDP was 12 months (range 3–99 months). The
median time from primary diagnosis to treatment was 23 months
(range 8–123 months). The median age was 64 years (range 50–
73) with a median pre-treatment PSA level of 47 ng ml
71 (range
0.1–3058) (Table 2). All patients had been previously treated with
lutenising hormone releasing hormone (LHRH) agonists (88%) or
orchidectomy (12%). Additionally 84% (21 out of 25) had received
prior palliative radiotherapy for painful bone metastases, 80% (20)
had received anti-androgens, 16% (four out of 25) were on diethyl-
stilbesterol and one patient had previously received cytotoxic
chemotherapy.
The median global Quality of Life score for the group was 58
out of 100 (range 17–100). Bone pain was reported by 80% (20
out of 25) of patients before treatment, with a median EORTC/
QLQ-C30 pain measure of 33 out of 100 (range 17–100).
Forty-four per cent (11 out of 25) had a bore scan score of 3,
36% (nine out of 25) a score of 2 and 20% (ﬁve out of 25) a score
of one. There was excellent correlation between pre-treatment bone
scan uptake and the uptake seen on Rhenium-186 planar scans.
There was no statistically signiﬁcant correlation between pre-treat-
ment Soloway score and rate of grade III haematological toxicity.
Prescribed activities of Re-186 are shown in Table 3. Four patients
were treated at the 3000 MBq activity level instead of three. The
actual administered activity varied from the prescribed activity
on average by 0.12%, range 78% to +8%. The median number
of re-infused mononuclear cells per kg was 9.4610
8 (range 3.7–
21.5). A median of 1.7610
6 CD 34 positive cells per kg of body
weight (range 0.3–6.7) were re-infused.
Toxicity
The major toxicity of Re-186 in this study was haematological
(Table 4, Figures 2 and 3). One patient out of three in the
5000 MBq activity level experienced grade III thrombocytopaenia
lasting 9 days. The patient group at this activity level was therefore
expanded to a total of six and a second patient developed grade III
thrombocytopaenia of 8 days duration, deﬁning ALT. Grade II
thrombocytopaenia occurred in 44% (11 out of 25). Platelet nadir
(median 83610
9 l



















At least 2 weeks
14 days





Age (years) 64 60–65
PSA (ng ml
71) 47 23–180
Alkaline phosphatase (U l
71) 172 80–469










Months on androgen ablation 20 12–70
Months from primary diagnosis to bone metastases 4 1–23
Months from diagnosis of bone metastases to treatment 13 7.5–20
EDTA clearance (ml per min) 101 91–111
Global Quality of Life (EORTC QLQ-C30) 58 33–75
Bone scan score
a 2 1–3
a(Soloway et al, 1988); 0: normal bone scan; 1: 56 metastases (all 550% the size of
a vertebral body); 2: 56, 520 metastases; 3: 420 metastases but not a superscan; 4:
superscan or 475% involvement of skeleton.
Table 3 Prescribed activity
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5150610
9 l
71 of 7 days (range 7–28).
Grade II leucopaenia was recorded in 36% (nine out of 25).
Sixteen per cent of patients (four out of 25) experienced grade
III leucopaenia all of who recovered within 7 days and no patients
developed neutropaenic sepsis. No grade IV leucopaenia was
recorded. The white cell nadir (median 2.95610
9, range 1.4–
4.9) occurred at a median of 24 days (range 14–35) with a
median time from nadir to a count above 3610
9 l
71 of 14 days
(range 14–21). The median nadir haemoglobin level (median
10.7 g l
71, range 8.5–13.1), occurred at a median of 20 days
(range 7–56). No patient had grade III anaemia, and 24% (six
out of 25) had grade II toxicity. Two patients had haemoglobin
levels less than 10 g dl
71 7 weeks post treatment, both of who
received transfusions. Twenty-four per cent (six out of 25)
required transfusion of red cells within 6 months of the therapy
however it is unclear whether this is related to the treatment as
many of these patients had extensive bone marrow inﬁltration.
There was no non-haematological toxicity noted in the patient
cohort.
Response
Although the primary objective of the study was to establish the
maximum tolerated activity of Rhenium-186 HEDP in prostate


























































Figure 2 White cell response.
Table 4 Haematological toxicity
Maximum Grade Grade Grade Grade Grade
CTC toxicity 0 I II III IV
Thrombocytopaenia 6 6 11 2 0
Leucopaenia 6 6 9 4 0





















































Figure 3 Platelet response.
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looked at PSA response as deﬁned by the recommendations of
the PSA Working Group (Bubley et al, 1999). A PSA response
(550% fall for 54 weeks) was seen in ﬁve out of 25 (20%)
patients all of whom received activity levels above 3500 MBq.
The median duration of response (PSA risen to 50% above nadir
level) was 3.5 months. When the presence of a PSA response was
analysed according to whether the patient received above or below
3500 MBq, there was a statistically signiﬁcant PSA activity
response seen (P=0.015, two-sided Fisher’s exact test). A fall in
PSA or stable levels was seen in 13 (52%) of patients at 1 month,
11 (44%) at 2 months, and eight (32%) at 3 months. Alkaline
phosphatase levels were reduced or stable in 92% (23 out of
25) at 1 month. The number responding reduced to 52% (13
out of 25), and 32% (eight out of 25), at 2 and 3 months respec-
tively with a median decrease of 33%, range 7–76%.
Follow up of pain scores using EORTC QLQ C-30 were avail-
able for 23 out of 25 patients. Ten patients had signiﬁcant pain
before treatment as deﬁned by a pain score 417. Of these, eight
patients had a pain response as deﬁned by 550% in pain score
lasting at least 4 weeks. Global quality of life assessments were
available for 23 out of 25 patients. An increase or decrease in
the global quality of life score of 25% lasting at least 4 weeks
was considered in improvement or deterioration respectively.
Eighteen patients had stable global quality of life scores, three
of whom demonstrated improvement. Five patients had deteriora-
tion in quality of life score.
Follow up
99mTc bones scans were taken between 6 and 12
weeks post treatment. We classiﬁed the reports of these scans as
stable (no new lesions), improved (reduced number of lesions),
or progressive disease (increased number of lesions). Forty-eight
per cent (12 out of 25) of scans showed stability or improvement
compared to the pre-treatment scans (Figure 4). The actuarial
survival at 1 year is 54% (95% CI 29.5–73.3%) and at 2 years is
23% (95% CI 6–46.6%).
DISCUSSION
Hormone refractory prostate cancer metastatic to bone is currently
incurable. Any useful treatment strategies in this group of patients
must aim to produce improvements or stability in quality of life.
The main problems experienced by patients with this condition
are pain, immobility and lethargy. With a potentially short survival,
especially in the progressive and symptomatic disease groups,
consideration must be given to the impact of a treatment protocol
on patients’ lives. This is important with regard to toxicity and time
involved in receiving the treatment particularly if it involves inpati-
ent stays. We have demonstrated the feasibility of treating patients
with progressive hormone refractory prostate cancer metastatic to
bone with escalating activities of Rhenium-186 HEDP using autolo-
gous peripheral blood stem cell support. The treatment is well
tolerated. Two patients receiving 5000 MBq experienced activity-
limiting toxicity in the form of grade III thrombocytopaenia. All
patients recovered from grade III haematological toxicity within
10 days. Patients spent a maximum of 4 days as inpatients for radio-
protection purposes. Three outpatient day admissions in total were
needed to harvest and then re-infuse the peripheral blood stem cells.
PSA responses were seen in ﬁve out of 12 patients receiving
activities of Re-186 greater than 3500 MBq. No patient had a
PSA response below this activity level. This represents a statistically
signiﬁcant activity (dose) response (Table 5). It is unclear whether
PSA responses have clinical signiﬁcance in this group of patients.
Some reports have associated PSA response and survival (Sridhara
et al, 1995; Bubley et al, 1999), while others have seen no statisti-
cally signiﬁcant association between palliative beneﬁt and PSA
response (Tannock et al, 1996).
Having demonstrated feasibility, and established a safe high
administered activity level, we now plan to proceed to formally test
response to treatment in a phase II single arm study. The main
endpoints of this study will be palliative, using quality of life, pain
score, and analgesic diaries. However we will also be analysing
bone scans for the disappearance of bone metastases and change
in biochemical parameters including PSA. Our preliminary assess-
ment suggests 22% of lesions are ablated (McCready et al, 1999). A
major consideration for the future role of this treatment strategy is
the cost beneﬁt. This will be addressed in our phase II trial where
the potential beneﬁt of the treatment will be established.
In tandem with our current study we are also investigating
methods of dosimetry. Relationships between the administered
activity and the dose to bone marrow and to individual metastasis
are being studied. Factors involved include body weight, glomeru-
lar ﬁltration rate and metastatic burden.
Our hope for the treatment is to prolong symptom free life for
patients with hormone refractory prostate cancer metastatic to bone.
In theory the radiation dose may be adequate to successfully ablate
micrometastases. Bone metastases which elicit enough osteoblastic
activity to be detected on bone scanning may be beyond ablation
by this method. Recent work (Tu et al, 2001) has shown a survival
advantage for the addition of strontium-89 to chemotherapy in
patients with advanced androgen-independent prostate cancer. We
are planning future studies to investigate the combination of









Figure 4 Pre-treatment bone scan (left) showing metastases in left ribs.
Bone scan (right) of the same patient 6 months post 5000 MbQ Rhenium-
186 HEDP showing disappearance of metastases, correlating with PSA fall
from 30 to 0.5 ng ml
71.
Table 5 Response by administered activity
53500 MBq 53500 MBq Fisher’s exact
n=13 n=12 test (two sided)
Number of 5Grade II 7 9 P=0.42
thrombocytopaenia
Number of 5Grade II 6 8 P=0.41
leucopaenia
PSA response 0 5 (42) P=0.015
Phase I Rhenium-186 HEDP study
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(11), 1715–1720high activity therapy with peripheral blood stem cell rescue using
other radionuclides with a short half-life may be valuable both in
prostate cancer and other malignancies. We have established that
acute toxicity is very acceptable even in this relatively elderly popu-
lation. Further follow-up and study will be required to ﬁnd out if
there are any more long term effects on bone marrow function from
effects on supporting bone marrow stromal cells.
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